These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

245 related items for PubMed ID: 28139739

  • 1. Combination of cephalosporins with vancomycin or teicoplanin enhances antibacterial effect of glycopeptides against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) and VISA.
    Lai CC, Chen CC, Chuang YC, Tang HJ.
    Sci Rep; 2017 Jan 31; 7():41758. PubMed ID: 28139739
    [Abstract] [Full Text] [Related]

  • 2. β-Lactam Combinations with Vancomycin Show Synergistic Activity against Vancomycin-Susceptible Staphylococcus aureus, Vancomycin-Intermediate S. aureus (VISA), and Heterogeneous VISA.
    Tran N, Rybak MJ.
    Antimicrob Agents Chemother; 2018 Jun 31; 62(6):. PubMed ID: 29555635
    [Abstract] [Full Text] [Related]

  • 3. Dalbavancin Alone and in Combination with Ceftaroline against Four Different Phenotypes of Staphylococcus aureus in a Simulated Pharmacodynamic/Pharmacokinetic Model.
    Kebriaei R, Rice SA, Stamper KC, Rybak MJ.
    Antimicrob Agents Chemother; 2019 Apr 31; 63(4):. PubMed ID: 30670436
    [Abstract] [Full Text] [Related]

  • 4. Performance of vancomycin and teicoplanin disk diffusion test in isogenic vancomycin non-susceptible Staphylococcus aureus.
    Wongthong S, Dutchanutouch K, Namsaengkang V, Chanawong A, Wilailuckana C, Lulitanond A.
    J Infect Dev Ctries; 2015 Feb 19; 9(2):157-64. PubMed ID: 25699490
    [Abstract] [Full Text] [Related]

  • 5. Underestimation of vancomycin and teicoplanin MICs by broth microdilution leads to underdetection of glycopeptide-intermediate isolates of Staphylococcus aureus.
    Vaudaux P, Huggler E, Bernard L, Ferry T, Renzoni A, Lew DP.
    Antimicrob Agents Chemother; 2010 Sep 19; 54(9):3861-70. PubMed ID: 20547791
    [Abstract] [Full Text] [Related]

  • 6. In-vitro bactericidal activity of cefpirome and cefamandole in combination with glycopeptides against methicillin-resistant Staphylococcus aureus.
    Bergeret M, Raymond J.
    J Antimicrob Chemother; 1999 Feb 19; 43(2):291-4. PubMed ID: 11252338
    [Abstract] [Full Text] [Related]

  • 7. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
    Zhanel GG, Voth D, Nichol K, Karlowsky JA, Noreddin AM, Hoban DJ.
    J Antimicrob Chemother; 2009 Aug 19; 64(2):364-9. PubMed ID: 19454524
    [Abstract] [Full Text] [Related]

  • 8. The Prevalence of Vancomycin-Intermediate Staphylococcus aureus and Heterogeneous VISA Among Methicillin-Resistant Strains Isolated from Pediatric Population in a Turkish University Hospital.
    Mirza HC, Sancak B, Gür D.
    Microb Drug Resist; 2015 Oct 19; 21(5):537-44. PubMed ID: 25919019
    [Abstract] [Full Text] [Related]

  • 9. Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection.
    MacGowan AP, Noel AR, Tomaselli S, Elliott HC, Bowker KE.
    Antimicrob Agents Chemother; 2011 Feb 19; 55(2):867-73. PubMed ID: 21078943
    [Abstract] [Full Text] [Related]

  • 10. Investigation of reduced susceptibility to glycopeptides among methicillin-resistant Staphylococcus aureus isolates from patients in Ireland and evaluation of agar screening methods for detection of heterogeneously glycopeptide-intermediate S. aureus.
    Fitzgibbon MM, Rossney AS, O'Connell B.
    J Clin Microbiol; 2007 Oct 19; 45(10):3263-9. PubMed ID: 17687008
    [Abstract] [Full Text] [Related]

  • 11. Prevalence of vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA among methicillin-resistant S. aureus with high vancomycin minimal inhibitory concentrations in Taiwan: A multicenter surveillance study, 2012-2013.
    Huang SH, Chen YC, Chuang YC, Chiu SK, Fung CP, Lu PL, Wang LS, Wu TL, Wang JT.
    J Microbiol Immunol Infect; 2016 Oct 19; 49(5):701-707. PubMed ID: 26320398
    [Abstract] [Full Text] [Related]

  • 12. Synergistic effect of vancomycin combined with cefotaxime, imipenem, or meropenem against Staphylococcus aureus with reduced susceptibility to vancomycin.
    Srisrattakarn A, Chaiyapoke C, Booncharoen S, Wongthong S, Chanawong A, Tippayawat P, Tavichakorntrakool R, Lulitanond A.
    Turk J Med Sci; 2021 Aug 30; 51(4):2150-2158. PubMed ID: 33705643
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The Potential Role of Sulbactam and Cephalosporins Plus Daptomycin Against Daptomycin-Nonsusceptible VISA and H-VISA Isolates: An in Vitro Study.
    Lai CC, Chen CC, Lu YC, Lin TP, Chen HJ, Su BA, Chao CM, Chuang YC, Tang HJ.
    Antibiotics (Basel); 2019 Oct 14; 8(4):. PubMed ID: 31615078
    [Abstract] [Full Text] [Related]

  • 15. Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
    Smith JR, Yim J, Raut A, Rybak MJ.
    Antimicrob Agents Chemother; 2016 Apr 14; 60(4):2352-8. PubMed ID: 26833159
    [Abstract] [Full Text] [Related]

  • 16. [The incidence and risk factors for heterogeneous vancomycin intermediate Staphylococcus aureus].
    Feng NN, Wang Q, Song YL, He LX, Zhou CM, Xie HM, Li HY.
    Zhonghua Nei Ke Za Zhi; 2013 Apr 14; 52(4):318-22. PubMed ID: 23925360
    [Abstract] [Full Text] [Related]

  • 17. Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia.
    Khatib R, Jose J, Musta A, Sharma M, Fakih MG, Johnson LB, Riederer K, Shemes S.
    J Antimicrob Chemother; 2011 Jul 14; 66(7):1594-9. PubMed ID: 21525024
    [Abstract] [Full Text] [Related]

  • 18. Emergence of vancomycin resistant Staphylococcus aureus (VRSA) from a tertiary care hospital from northern part of India.
    Tiwari HK, Sen MR.
    BMC Infect Dis; 2006 Oct 26; 6():156. PubMed ID: 17067393
    [Abstract] [Full Text] [Related]

  • 19. Detection of Staphylococcus aureus isolates with heterogeneous intermediate-level resistance to vancomycin in the United States.
    Richter SS, Satola SW, Crispell EK, Heilmann KP, Dohrn CL, Riahi F, Costello AJ, Diekema DJ, Doern GV.
    J Clin Microbiol; 2011 Dec 26; 49(12):4203-7. PubMed ID: 21976769
    [Abstract] [Full Text] [Related]

  • 20. In vitro activity of fosfomycin in combination with vancomycin or teicoplanin against Staphylococcus aureus isolated from device-associated infections unresponsive to glycopeptide therapy.
    Pistella E, Falcone M, Baiocchi P, Pompeo ME, Pierciaccante A, Penni A, Venditti M.
    Infez Med; 2005 Jun 26; 13(2):97-102. PubMed ID: 16220029
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.